Generic Name and Formulations:
Gadoversetamide 330.9mg/mL; soln for IV inj; preservative-free.
Indications for OPTIMARK:
For use with magnetic resonance imaging (MRI) in patients with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues. For use with MRI to provide contrast enhancement and facilitate visualization of lesions with abnormal vascularity in the liver in patients who are highly suspect for liver structural abnormalities on computed tomography.
Give as bolus peripheral IV injection at a dose of 0.2mL/kg at a rate of 1–2mL/sec.
Chronic, severe renal disease (GFR <30mL/min/1.73m2) or acute renal injury.
Increase risk for nephrogenic systemic fibrosis in patients with impaired elimination of gadolinium-based contrast agents. Screen for acute kidney injury and other conditions that reduce renal function. Use lowest possible dose. Do not exceed recommended dose; allow sufficient period of time for elimination prior to re-administration. Sickle cell anemia and other hemoglobinopathies. Hemolytic anemias. History of asthma, allergy or other respiratory disorders. Anaphylactoid reactions possible; have emergency resuscitative equipment available. Monitor for hypersensitivity during and for several hours after injection; discontinue if occurs. Pregnancy (Cat.C). Nursing mothers: not recommended; discard breast milk up to 72hrs after injection.
Interference in serum iron, copper, zinc, and calcium measurements.
Gadolinium-based contrast agent.
Headache, vasodilation, taste perversion, dizziness, nausea, paresthesia; anaphylaxis (may be fatal).
Vials (5mL, 10mL, 15mL, 20mL)—10; Syringes (10mL, 15mL, 20mL, 30mL)—10
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D